Anticorps Monoclonal Anti - BRD7 produit en rat, environ 1,0 mg / mL, clone BRM 2D3,immunoglobulin purifié, solution aqueuse tamponnée

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Monoclonal Anti-BRD7 antibody produced in rat has been used in several immunochemical techniques including immunoblotting immunoprecipitation immunocytochemistry

Biochem/physiol Actions

Bromodomain containing (BRD7) inhibits cell growth and cell cycle progression by transcriptional regulation of some cell cycle-related genes as well as some important molecules involved in ras/mitogen-activated protein kinase(MEK)/extracellular-signal-regulated kinase (ERK) and retinoblastoma tumor suppressor protein (RB)/ E2 factor (E2F) pathways. Its transcriptional down regulation has been shown to be critical to the pathogenesis of nasopharyngeal carcinoma (NPC). Specifically, DNA methylation decreases the expression of BRD7 in NPC cells. Furthermore, DNA methylation of BRD7 promoter is increased in the tumor and in matched blood samples from NPC patients than in blood samples from healthy individuals. Therefore, it has been suggested that DNA methylation of BRD7 promoter might act as a potential diagnostic marker in NPC.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Monoclonal Anti-BRD7 (rat IgG2a isotype) is derived from the hybridoma BRM 2D3 produced by the fusion of mouse myeloma cells (P3X63Ag8.653) and splenocytes from rat immunized with a fusion protein expressing a fragment of human BRD7. Bromodomain containing (BRD7) is a novel bromodomain gene.

Physical form

Solution in 0.01M phosphate buffered saline pH 7.4, containing 15 mM sodium azide.